SEMA7A and breast cancer: Using immunohistochemistry and an AngioSense probe, an in vivo blood pool vascular fluorescent imaging agent, we determined the in vivo role of SEMA7A by comparing angiogenesis in mice bearing scramble shRNA DA-3 mammary tumors with those bearing SEMA7A shRNA knockdown DA-3 mammary tumors.